iA Global Asset Management Inc. Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

iA Global Asset Management Inc. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,652 shares of the company’s stock, valued at approximately $306,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Plato Investment Management Ltd boosted its stake in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank grew its position in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after buying an additional 4,100 shares during the period. KBC Group NV increased its holdings in Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after buying an additional 8,332 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Neurocrine Biosciences by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after acquiring an additional 7,597 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Neurocrine Biosciences by 48.5% in the third quarter. Victory Capital Management Inc. now owns 204,205 shares of the company’s stock valued at $23,529,000 after purchasing an additional 66,662 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $128.96 on Wednesday. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The company’s 50 day moving average price is $120.91 and its 200-day moving average price is $130.82. The stock has a market capitalization of $13.06 billion, a price-to-earnings ratio of 34.57 and a beta of 0.34.

Wall Street Analyst Weigh In

Several research firms recently commented on NBIX. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Barclays decreased their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, Royal Bank of Canada dropped their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.